Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, corn silk extract treatment improved symptoms of testosterone-induced BPH by reducing specific mRNA expression and decreasing levels of 5α-R2, DHT, and PSA.

The study found that ezetimibe effectively reduced prostate enlargement in an animal model of benign prostatic hyperplasia, suggesting it as a potential alternative or complementary treatment.

This review discusses the pharmacologic effects, safety, and efficacy of dutasteride and finasteride for BPH, finding similar clinical benefits but greater DHT reduction with dutasteride and reports no new trial results.

This review discusses the potential uses of 5α-reductase inhibitors for conditions ranging from benign prostatic hyperplasia to skin disorders like acne and male pattern baldness, but it reports no new clinical results.

This study reported that newly synthesized phenanthridin-3-one derivatives effectively inhibit human steroid 5-α-reductase.

This study found that 5-alpha-reductase inhibitor monotherapy for symptomatic benign prostatic hyperplasia showed some clinical benefit over placebo but was linked to a higher incidence of sexual side effects.

This review discusses the stratification and management of male patients with lower urinary tract symptoms and benign prostatic hyperplasia in primary care and reports no new clinical results.

This study found that a new hybrid compound designed from finasteride and epristeride was a potent inhibitor of 5α-reductase with a mechanism similar to finasteride.

This paper reviews the role of pharmacokinetic/pharmacodynamic modeling in drug development, emphasizing its application for drug dosing guidance, safety resolution, and therapeutic monitoring improvement, without presenting new clinical results.

This article discusses the potential health risks associated with long-term use of finasteride and dutasteride for prostate and hair loss treatments, suggesting risks may include non-alcoholic fatty liver disease, insulin resistance, type 2 diabetes, and other metabolic issues.

This study constructed a model to predict finasteride's inhibitory activity on 5α-reductase type 2 and calculated that a 1 μM plasma concentration, after 50 mg administration, matches prostate inhibition levels.

In this study, FCE 28260 showed greater potency than finasteride in inhibiting 5α-reductase enzymes and reducing prostate DHT levels in rats.

This study found an association between higher phthalate exposure and increased incidence of precocious puberty in girls, suggesting a need to reduce children's exposure to these endocrine disruptors.

This study suggests that DHT may have a less potent effect on the prostate compared to testosterone while maintaining safety and similar effects on erythropoiesis and lipids.

Androgens and SARMs play a role in body mass, frailty, skin health, and hair growth, and are used in treating prostate cancer, acne, and hair loss, with potential for new uses and improved versions in the future.

This review discusses the potential benefits of pumpkin seed oil for men's health, particularly in conditions such as benign prostatic hyperplasia, overactive bladder, and androgenic alopecia, but reports no new clinical results.

This review discusses the effects of 5ARI drugs on male reproductive parameters, reporting potential decreases in sperm count and motility more significantly in men with pre-existing oligozoospermia, but does not provide fertility outcomes.

This study found that combining 5-alpha reductase inhibitors with alpha-blockers provided the best symptomatic relief and reduced the risk of clinical progression for BPH, while PDE5 inhibitors could offset sexual side effects.

This article offers strategies for managing acne effectively and safely, emphasizing treatment optimization, patient tailoring, and addressing antimicrobial resistance, but reports no new clinical results.

This review discusses sexual dysfunction as a side effect of α-blockers and 5-ARIs for BPH/LUTS, highlighting methodological flaws in existing studies and the need for more rigorous research.

This study found that α-spinasterol treatment significantly reduced testosterone propionate-induced prostatic hyperplasia in rats, suggesting potential benefits for managing benign prostatic hyperplasia.

This study found that low doses of bisphenol A may increase proliferation of the ventral prostate in adult rats by altering the estrogen to androgen ratio and gene expression.

This review found that finasteride monotherapy for managing LUTS/BPH significantly reduced prostate volume and improved symptoms, with sexual dysfunctions reported as notable side effects compared to placebo, but emphasizes the need for more comprehensive studies.

This review examines the use of tadalafil and finasteride as a combined therapy for BPH, suggesting it may effectively reduce treatment-related sexual adverse events and improve symptom relief.

This study found that several dehydroepiandrosterone ester derivatives effectively reduced prostate and seminal vesicle weight in gonadectomized hamsters treated with testosterone, demonstrating potential antiandrogen effects comparable to Finasteride.

This study explored how modifying the 8-substituent of 8-bromobenzoquinolinone affects its selectivity in inhibiting both 5 alpha-reductase isozymes in the scalp.

Finasteride can cause enlarged breasts.

This study found that using anhydrous cerium(III) chloride with alkyl Grignard reagents significantly improved the addition to sterically hindered 17-ketosteroids, resulting in high yields and stereoselectivity.

In this study, researchers found no significant difference in bladder cancer incidence between men treated with finasteride and those given a placebo, suggesting that reduced dihydrotestosterone levels may not impact bladder cancer risk.

This study generated a pharmacophoric model for both isoforms of steroidal 5α-reductase using 6-azasteroids, providing a structural framework for designing new inhibitors.